Downregulation of E-cadherin was found to be associated with progression, promotion, and poor prognosis, and changes in E-cadherin expression were documented in gastric, prostate, liver, and colon cancers [42,43,44]. This evidence concerns the gene CDH1 and colonic neoplasm.